X Wu
5 Papers
1 Citations
X Wu is an academic researcher. The author has contributed to research in topics: Medicine & Composite number. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Corrosion behavior of novel titanium-based composite with engineering 3D artificial nacre-like structures
TL;DR: In this article , a titanium-based composite (TCCP) with engineering 3D artificial nacre-like structures consisting of commercial purity titanium (CPTi, served as brick) and Ti6Al4V (TC4), served as mud was firstly produced by coupling selective laser melting and hot isostatic pressing (HIP).
18
SU-E-J-244: Development and Validation of a Knowledge Based Planning Model for External Beam Radiation Therapy of Locally Advanced Non-Small Cell Lung Cancer
Z Liu,E Larsen,S. Bahamondes,M Choi,J Li,K Cranford,C Hayes,A Grow,Y Zheng,X Wu,S Pai,A Kennedy +11 more
TL;DR: A KBP model was developed and validated for radiotherapy of LA-NSCLC in a commercial treatment planning system and the clinical implementation may improve the consistency of IMRT/VMAT planning.
1
Specificity of cortical area and thickness as biomarkers for comorbid internalizing and externalizing mental disorders in pre-adolescence
Kai Yu,Z. Liu,K. Zhang,X Wu,Bernhard Becker,H Fan,J. Zhao,Guozhao Dong,X K Zhao,J. Feng,Barbara J. Sahakian,Trevor W. Robbins,Gunter Schumann,Lena Palaniyappan,J. Zhang +14 more
TL;DR: The emergence of comorbidity across distinct clusters of psychopathology is unlikely to be a simple additive neurobiological effect, and distinct risk-adaptation processes, with unique genetic and cell-specific factors may underlie SA and CT changes.
1
79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
X Wu,Liming Xia,J. Wang,C. Wang,Q. Zhang,J. Zhu,Qian Wen Rao,H. Cheng,Z. Liu,Y Yin,Xin Lei Ai,Kurban Gulina,H. S. Zheng,X. Luo,B Chang,L. Li,H. Liu,Y. Li +17 more
TL;DR: Zimberelimab as discussed by the authors is a fully human anti-PD-1 monoclonal antibody with high affinity and selectivity for PD-1, which has been shown to be effective in patients with programmed death ligand-1-positive recurrent or metastatic cervical cancer.
[Inhibitor of growth protein-2 silencing alleviates angiotensin Ⅱ-induced cardiac remodeling in mice by reducing p53 acetylation].
Z. Liu,Xiaotang Qiu,H. Yang,X Wu,W. Ye +4 more
TL;DR: Ing2 silencing obviously alleviated AngⅡ-induced cardiac function decline, as shown by decreased LVEDD and LVESD and increased LVEF and LVFS, improved myocardial mitochondrial damage and myocardian hypertrophy and fibrosis, and inhibited cardiomyocyte apoptosis.